THR-123 Special Manufacturing Question

[Peppers2 21501]

Hello -

Does anyone know who could manufacture a specific peptide not available on typical vendor lists? I’m looking to have the below peptide manufactured as it has shown reversal of diabetes in studies. Thrasos manufactured it for AKI but shelved it when it didn’t quite work out as planned.

THR-123 is a 16-amino acid cyclic peptide BMP-7 mimetic (ALK3 agonist). Chemical Breakdown

Sequence (one-letter code): CYFDDSSNVLCKKYRS

Full Sequence: Cys-Tyr-Phe-Asp-Asp-Ser-Ser-Asn-Val-Leu-Cys-Lys-Lys-Tyr-Arg-Ser

Cyclization: Disulfide bridge between Cys1 and Cys11.

Molecular Formula (free base): C₈₃H₁₂₄N₂₂O₂₇S₂

Molecular Weight: 1926.13 Da (free base)

Sequence Shortening: Often listed as CYFDDSSNVLCKKYRS (Cys1-Cys11 disulfide)

 

[Turbo-Farmer]

https://www.medchemexpress.com/thr-...b3HZkLVsX98Tgb7apJEXx3FPgmgW_AC_B-dfuB5JAyLDW

It’s already for sale in a bulk form. A peptide sequencer is not terribly expensive. The expensive part of the manufacturing process is the following purification process using liquid chromatography.

After which you would need to formulate a liquid mixture, fill the vials and then onto the lyophilizer.

This is all doable if you have the resources, However it would be prohibitively expensive.

Peptide manufacturing is subject to the economy of scale, where the more you manufacture the lower the cost.

It appears as though “THR-123” is a fairly new compound. As I have only seen phase one trials (safety). It maybe worth waiting until the phase two trial (efficacy) start to become available. It maybe worth waiting, it may turn out to work similar to AOD-9604, which worked for rats but wasn’t as promising for humans.

Unfortunately the way the pharmaceutical industry works in the USA, there’s always more incentive for a lifetime subscription than for a cure.

 

[Peppers2 21501]

Yes, Thrasos also created THR-184, which was used on humans in phase II trials; however, I don’t believe the THR-123 version has had human trials. THR-123 Human relevance: Pathways were conserved in human pancreatic slices; earlier BMP-7 work had already shown beta-cell regeneration in T1D donor tissue ex vivo.

THR-184 → Optimized later version; advanced to Phase 1/2 clinical trials for preventing cardiac surgery-associated acute kidney injury (AKI).

THR-123 diabetes research centers on its potential to regenerate insulin-producing pancreatic beta cells in situ (directly within the pancreas) as a pharmacological approach to treat insulin-dependent diabetes, particularly type 1 diabetes (T1D).

 

[lessthanhalf]

It is listed as being available from fairly standard research suppliers, getting them to sell you it might be a problem, unless you have a doctorate and a lab address to ship it to. It is possible to get custom peptides made but it is likely to be quite expensive and may also run into the only supplying to a lab problem. The "dodgy " sellers who sell peptides for people to use as therapies, but mark them as not for human use usually have a small range of products.

If you are seriously pursuing taking a drug at this stage of development, you would really need to do some serious research to understand the issues and risks involved, phase 1 studies exclude some risks, but will not find less common effects or long term ones.